Down 50%, this FTSE dividend stock looks like a steal to me

This FTSE stock’s been crushed if not quite left for dead. However, Edward Sheldon believes it’s capable of a big rebound at some stage.

| More on:
Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

UK stocks, as a whole, have had a decent run in 2024. Year to date, the FTSE All-Share index is up about 5%.

Yet there are still many stocks miles off their highs and have the potential to soar in the years ahead. Here’s a look at one that’s currently trading around 50% below its all-time highs.

Down a whopping 50%

Smith & Nephew’s (LSE: SN.) a medical technology business that’s focused on hip and knee implants, robotic surgery solutions, and trauma products. A FTSE 100 company, it currently has a market-cap of around £9bn.

As a long-term investor who likes to back big trends, I’ve always thought S&N has bags of potential from an investment perspective. This is due to the fact that the world’s population is ageing rapidly. As we age, our joints tend to break down. My grandfather was a great example here – after turning 70, he needed both knees and a hip replaced (too much golf).

The stock hasn’t done well in recent years though. That’s because it faced challenges due to the coronavirus. This significantly limited the number of joint replacement surgeries that could take place globally. As a result of this disruption, the company’s share price has fallen from near-£20 to around £10.

Poised for a rebound

The outlook’s now improving though. Across the world, elective surgeries are taking place again and there’s quite a large backlog for joint replacement procedures.

For example, a report published this month in the Medical Journal of Australia said that its national annual caseload would need to increase by 16% by the end of 2024, 10% by the end of 2025, or 8% by the end of 2026 to clear the backlog accumulated during the pandemic.

This leads me to believe there’s potential for a share price rebound here. Currently, the forward-looking P/E ratio here is just 12 using next year’s earnings per share forecast. That’s low for a high-quality healthcare company. Especially with analysts expecting earnings growth of 11% this year and 17% next. Given this low valuation, I believe those who are willing to be patient with this stock could be rewarded.

It’s worth noting that analysts at JPMorgan recently raised their target price for Smith & Nephew to 1,381p from 1,300p. That’s about 37% higher than the current share price. If the stock was to hit that level, investors could be looking at a total return of about 40% over the next 12 months once the 3% dividend yield is factored in.

I’m bullish

Now a key risk to the investment case is GLP-1 weight loss drugs like Wegovy. The uncertainty created by these drugs (in relation to demand for joint replacements) is one reason the share price is still down in the dumps.

However, it’s still too early to know if they’ll have any long-term impact on the industry. Some analysts believe they could actually help companies like Smith & Nephew as they’ll enable more people to qualify for surgery.

Personally, I believe that the outlook for this company remains attractive due to the ageing population. And at the current share price, I think its shares are a steal.

I actually wouldn’t be surprised to see a takeover bid for the company. In the past, it’s often been the subject of takeover speculation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Value Shares

Investing Articles

Are Burberry shares a bargain or a value trap?

Appearances can be misleading in the stock market. Shares that look like a bargain can turn out to be a…

Read more »

Investing Articles

3 ways Labour could impact the Rolls-Royce share price

Labour have swept to power on a pro-worker, pro-business ticket. But how could the new government influence the Rolls-Royce share…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Is time up for Watches of Switzerland shares?

Many companies have seen volatility over the last few years, but with the Watches of Switzerland share price down 38%…

Read more »

Solar panels fields on the green hills
Investing Articles

With the BP share price down 8% this week, I think it’s time to look elsewhere

Mark David Hartley is shifting his focus to renewable energy as the BP share price falls further into decline. But…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

3 FTSE 100 stock bargains to consider buying right now

There may be a valuation re-rating coming for large-cap FTSE 100 companies, so I'm targeting some of these bargain stocks…

Read more »

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Here’s why I’m watching the Glencore share price

The mining sector has always been volatile, but with some recent strategic moves, I'm watching the Glencore share price even…

Read more »